PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21502544-1	2011	PURPOSE: The addition of cetuximab to irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer (mCRC) was shown to reduce the risk of disease progression and increase the chance of response in patients with KRAS wild-type disease.	FOLFIRI regimen	80-87	KRAS proto-oncogene, GTPase	Homo sapiens	258-262	
21502544-7	2011	The addition of cetuximab to FOLFIRI in patients with KRAS wild-type disease resulted in significant improvements in overall survival (median, 23.5 v 20.0 months; hazard ratio [HR], 0.796; P = .0093), progression-free survival (median, 9.9 v 8.4 months; HR, 0.696; P = .0012), and response (rate 57.3% v 39.7%; odds ratio, 2.069; P < .001) compared with FOLFIRI alone.	FOLFIRI regimen	29-36	KRAS proto-oncogene, GTPase	Homo sapiens	54-58	
21502544-9	2011	KRAS mutation status was confirmed as a powerful predictive biomarker for the efficacy of cetuximab plus FOLFIRI.	FOLFIRI regimen	105-112	KRAS proto-oncogene, GTPase	Homo sapiens	0-4	
21502544-11	2011	CONCLUSION: The addition of cetuximab to FOLFIRI as first-line therapy improves survival in patients with KRAS wild-type mCRC.	FOLFIRI regimen	41-48	KRAS proto-oncogene, GTPase	Homo sapiens	106-110